

Jaime R Merchan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12122693/publications.pdf>

Version: 2024-02-01

40
papers

5,019
citations

471509

17
h-index

377865

34
g-index

40
all docs

40
docs citations

40
times ranked

6061
citing authors

#	ARTICLE	IF	CITATIONS
1	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 384, 1289-1300.	27.0	956
2	Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5063-5063.	1.6	1
3	Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 837-848.	10.7	262
4	The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, 135-139.	1.4	11
5	Percutaneous Image-Guided Irreversible Electroporation for the Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 342-348.	0.5	100
6	Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer. <i>Molecular Cancer Research</i> , 2017, 15, 1410-1420.	3.4	27
7	A phase I study of enfortumab vedotin (ASG-22CE; ASG-22ME): Updated analysis of patients with metastatic urothelial cancer.. <i>Journal of Clinical Oncology</i> , 2017, 35, 106-106.	1.6	22
8	Notch pathway inhibition with LY3039478 in adenoid cystic carcinoma (ACC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6024-6024.	1.6	8
9	Activity of RX-3117, an oral antimetabolite nucleoside, in patients with pancreatic cancer: Preliminary results of stage 1 of the phase 1a/2b.. <i>Journal of Clinical Oncology</i> , 2017, 35, 445-445.	1.6	2
10	The evolving landscape of oncolytic virotherapy (OV) clinical trials (CT): Meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14636-e14636.	1.6	0
11	A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2016, 22, 3209-3217.	7.0	5
12	2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3 β Activation. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 264-275.	4.1	26
13	Results of a phase 1 study of single agent RX-3117: An oral antimetabolite nucleoside to treat solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2555-2555.	1.6	1
14	Anti-tumor activity, safety and pharmacokinetics (PK) of ASG-22CE (ASG-22ME; enfortumab vedotin) in a phase I dose escalation trial in patients (Pts) with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 4533-4533.	1.6	5
15	Prevalence of radiologic evidence of metastatic pancreatic ductal adenocarcinoma (PDAC) at first post-operative restaging studies in patients (pts) undergoing pancreatic cancer surgery with curative intent.. <i>Journal of Clinical Oncology</i> , 2016, 34, 225-225.	1.6	1
16	Targeting tumor vasculature through oncolytic virotherapy: recent advances. <i>Oncolytic Virotherapy</i> , 2015, 4, 169.	6.0	19
17	Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 485-493.	2.3	14
18	Full dose neoadjuvant FOLFIRINOX is associated with prolonged survival in patients with locally advanced pancreatic adenocarcinoma. <i>Pancreatology</i> , 2015, 15, 667-673.	1.1	73

#	ARTICLE	IF	CITATIONS
19	Gemcitabine (Gem) and nab-paclitaxel (nab-P) in patients (pts) with refractory advanced pancreatic cancer.. Journal of Clinical Oncology, 2015, 33, 413-413.	1.6	2
20	The value of tissue protein expression as a predictor of efficacy for first- or second-line therapy (tx) in metastatic ductal pancreas cancer (PDAC) in patients (pts) receiving either gemcitabine (G)-based tx or 5FU (F)-based tx.. Journal of Clinical Oncology, 2015, 33, 460-460.	1.6	0
21	Exploring phosphatase and tensin homolog (PTEN) loss via immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) as a potential predictive marker for response to everolimus in patients (pts) with neuroendocrine tumors (NET).. Journal of Clinical Oncology, 2015, 33, 333-333.	1.6	0
22	Preclinical safety and activity of recombinant VSV- Δ FN Δ 2 in an immunocompetent model of squamous cell carcinoma of the head and neck. Head and Neck, 2014, 36, 1619-1627.	2.0	14
23	Percutaneous irreversible electroporation (IRE) in the management of pancreatic cancer.. Journal of Clinical Oncology, 2014, 32, e15249-e15249.	1.6	2
24	Phase 1 trial of zoptarelin doxorubicin (Zop-Dox) in advanced unresectable or metastatic urothelial carcinoma (UC) patients who failed platinum-based chemotherapy.. Journal of Clinical Oncology, 2014, 32, e15517-e15517.	1.6	0
25	Updated survival analysis of patients (pts) with unresectable (UR) or borderline resectable (BR) locally advanced pancreatic adenocarcinoma (LAPC) treated with neoadjuvant FOLFIRINOX.. Journal of Clinical Oncology, 2014, 32, e15197-e15197.	1.6	0
26	Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. Molecular Carcinogenesis, 2013, 52, 218-228.	2.7	17
27	Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 2013, 369, 722-731.	27.0	1,648
28	A Phase II Trial of nab-Paclitaxel as Second-line Therapy in Patients With Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2013, 36, 151-156.	1.3	94
29	Preclinical study of cytotoxicity and predictive markers of response to dual inhibition of PI3K and mTORC1/2 signaling by NVP-BE235 with or without paclitaxel or nab-paclitaxel as a new therapeutic strategy in pancreatic cancer cell lines.. Journal of Clinical Oncology, 2013, 31, e15007-e15007.	1.6	1
30	Long-term response in a patient with urothelial cancer (UC) treated with AEZS-108.. Journal of Clinical Oncology, 2013, 31, e15596-e15596.	1.6	0
31	Role of Plasminogen Activator Inhibitor-1 in Urokinase's Paradoxical <i>In Vivo</i> Tumor Suppressing or Promoting Effects. Molecular Cancer Research, 2012, 10, 1271-1281.	3.4	17
32	Phase II Study of Gemcitabine, Oxaliplatin, and Cetuximab in Advanced Pancreatic Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 446-450.	1.3	16
33	A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer, 2012, 12, 199.	2.6	198
34	Antiangiogenic Activity of 2-Deoxy-D-Glucose. PLoS ONE, 2010, 5, e13699.	2.5	92
35	Tumor and Vascular Targeting of a Novel Oncolytic Measles Virus Retargeted against the Urokinase Receptor. Cancer Research, 2009, 69, 1459-1468.	0.9	64
36	Sunitinib in Patients With Metastatic Renal Cell Carcinoma. JAMA - Journal of the American Medical Association, 2006, 295, 2516.	7.4	1,111

#	ARTICLE	IF	CITATIONS
37	Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: Potentiation by Cox-2 inhibition. <i>International Journal of Cancer</i> , 2005, 113, 490-498.	5.1	79
38	Targeted Measles Virus Vector Displaying Echistatin Infects Endothelial Cells via $\alpha_5\beta_1$ and Leads to Tumor Regression. <i>Cancer Research</i> , 2005, 65, 5292-5300.	0.9	63
39	Antiangiogenic property of human thrombin. <i>Microvascular Research</i> , 2003, 66, 1-14.	2.5	13
40	In Vitro and In Vivo Induction of Antiangiogenic Activity by Plasminogen Activators and Captopril. <i>Journal of the National Cancer Institute</i> , 2003, 95, 388-399.	6.3	55